Rocket Pharmaceuticals Inc. Insider Trading

RCKT

Last 12 months

Insiders bought 34K and sold 864K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. General Counsel Martin Wilson sold 256K on Sep 11, 11% of their stake, outside a plan.

Net open-market

−830K

1 buy · 25 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 6

executives and directors

Last open-market buy

Jan 2026

Jan 2, 2026

Get an email when RCKT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 11	Martin Wilson General Counsel	SoldNo plan	75,364	$3.40	256K	11%	Form 4
Aug 18	Martin Wilson General Counsel	SoldNo plan	631	$3.38	2K	<0.1%	Form 4
Aug 18	Gaurav Shah CEO	SoldNo plan	2,293	$3.38	8K	0.2%	Form 4
Aug 13	Gaurav Shah CEO	SoldNo plan	2,837	$3.38	10K	0.2%	Form 4
Aug 13	Martin Wilson General Counsel	SoldNo plan	3,493	$3.38	12K	0.5%	Form 4
Aug 11	Christopher James Stevens Chief Operating Officer	SoldNo plan	36,658	$3.50	128K	6.8%	Form 4
Aug 11	Sarbani Chaudhuri See Remarks	SoldNo plan	4,701	$3.50	16K	1.8%	Form 4
May 21	Gaurav Shah CEO	SoldNo plan	55,684	$3.09	172K	3.7%	Form 4
May 19	Gaurav Shah CEO	SoldNo plan	2,409	$3.01	7K	0.2%	Form 4
May 19	Martin Wilson General Counsel	SoldNo plan	662	$3.01	2K	<0.1%	Form 4
May 19	John Militello See Remarks	SoldNo plan	384	$3.01	1K	0.4%	Form 4
May 13	Martin Wilson General Counsel	SoldNo plan	3,361	$3.61	12K	0.5%	Form 4
May 13	Gaurav Shah CEO	SoldNo plan	2,728	$3.61	10K	0.2%	Form 4
May 13	John Militello See Remarks	SoldNo plan	855	$3.61	3K	0.9%	Form 4
May 7	Sarbani Chaudhuri See Remarks	SoldNo plan	17,650	$3.84	68K	6.2%	Form 4
Feb 18	John Militello See Remarks	SoldNo plan	1,157	$3.34	4K	1.3%	Form 4
Feb 18	Gaurav Shah CEO	SoldNo plan	5,990	$3.34	20K	0.4%	Form 4
Feb 18	Martin Wilson General Counsel	SoldNo plan	1,376	$3.34	5K	0.2%	Form 4
Feb 13	Martin Wilson General Counsel	SoldNo plan	12,253	$3.31	41K	1.8%	Form 4
Feb 13	John Militello See Remarks	SoldNo plan	3,726	$3.31	12K	3.9%	Form 4
Feb 13	Gaurav Shah CEO	SoldNo plan	12,279	$3.31	41K	0.8%	Form 4
Jan 2	Elisabeth Bjork Director	Bought	10,000	$3.44	34K	25%	Form 4
Nov 18, 2025	John Militello See Remarks	SoldNo plan	1,086	$2.98	3K	1.6%	Form 4
Nov 18, 2025	Jonathan David Schwartz See Remarks	SoldNo plan	2,545	$2.98	8K	0.8%	Form 4
Nov 18, 2025	Gaurav Shah CEO	SoldNo plan	6,276	$2.98	19K	0.5%	Form 4
Nov 18, 2025	Martin Wilson General Counsel	SoldNo plan	1,646	$2.98	5K	0.4%	Form 4
Oct 14, 2025	John Militello See Remarks	SoldNo plan 4 parts	28,918	$3.96 average	115K	30%	Form 4
Aug 27, 2025	Elisabeth Bjork Director	Bought	10,000	$3.41	34K	33%	Form 4
Aug 18, 2025 – Aug 19, 2025	John Militello See Remarks	SoldNo plan 2 parts	1,060	$3.05 average	3K	1.9%	Form 4
Aug 18, 2025 – Aug 19, 2025	Jonathan David Schwartz See Remarks	SoldNo plan 2 parts	2,485	$3.05 average	8K	1.1%	Form 4
Aug 18, 2025 – Aug 19, 2025	Martin Wilson General Counsel	SoldNo plan 2 parts	1,592	$3.04 average	5K	1.2%	Form 4
Aug 14, 2025	Jonathan David Schwartz See Remarks	SoldNo plan	11,161	$3.02	34K	4.7%	Form 4
Aug 14, 2025	John Militello See Remarks	SoldNo plan	7,043	$3.02	21K	11%	Form 4
Aug 14, 2025	Martin Wilson General Counsel	SoldNo plan	12,109	$3.02	37K	8.1%	Form 4
Jul 3, 2025	Aaron Ondrey Chief Financial Officer	SoldNo plan	1,477	$2.88	4K	1.1%	Form 4
May 20, 2025	John Militello See Remarks	SoldNo plan	357	$6.45	2K	0.6%	Form 4
May 20, 2025	Jonathan David Schwartz See Remarks	SoldNo plan	801	$6.45	5K	0.3%	Form 4
May 20, 2025	Kinnari Patel See Remarks	SoldNo plan	767	$6.45	5K	0.1%	Form 4
May 20, 2025	Gaurav Shah CEO	SoldNo plan	2,253	$6.45	15K	0.2%	Form 4
May 20, 2025	Martin Wilson General Counsel	SoldNo plan	587	$6.45	4K	0.4%	Form 4

Sep 11No plan
Martin Wilson
General Counsel · sold 75,364 at $3.40
256K
11% of stake
Aug 18No plan
Martin Wilson
General Counsel · sold 631 at $3.38
2K
<0.1% of stake
Aug 18No plan
Gaurav Shah
CEO · sold 2,293 at $3.38
8K
0.2% of stake
Aug 13No plan
Gaurav Shah
CEO · sold 2,837 at $3.38
10K
0.2% of stake
Aug 13No plan
Martin Wilson
General Counsel · sold 3,493 at $3.38
12K
0.5% of stake
Aug 11No plan
Christopher James Stevens
Chief Operating Officer · sold 36,658 at $3.50
128K
6.8% of stake
Aug 11No plan
Sarbani Chaudhuri
See Remarks · sold 4,701 at $3.50
16K
1.8% of stake
May 21No plan
Gaurav Shah
CEO · sold 55,684 at $3.09
172K
3.7% of stake
May 19No plan
Gaurav Shah
CEO · sold 2,409 at $3.01
7K
0.2% of stake
May 19No plan
Martin Wilson
General Counsel · sold 662 at $3.01
2K
<0.1% of stake
May 19No plan
John Militello
See Remarks · sold 384 at $3.01
1K
0.4% of stake
May 13No plan
Martin Wilson
General Counsel · sold 3,361 at $3.61
12K
0.5% of stake
May 13No plan
Gaurav Shah
CEO · sold 2,728 at $3.61
10K
0.2% of stake
May 13No plan
John Militello
See Remarks · sold 855 at $3.61
3K
0.9% of stake
May 7No plan
Sarbani Chaudhuri
See Remarks · sold 17,650 at $3.84
68K
6.2% of stake
Feb 18No plan
John Militello
See Remarks · sold 1,157 at $3.34
4K
1.3% of stake
Feb 18No plan
Gaurav Shah
CEO · sold 5,990 at $3.34
20K
0.4% of stake
Feb 18No plan
Martin Wilson
General Counsel · sold 1,376 at $3.34
5K
0.2% of stake
Feb 13No plan
Martin Wilson
General Counsel · sold 12,253 at $3.31
41K
1.8% of stake
Feb 13No plan
John Militello
See Remarks · sold 3,726 at $3.31
12K
3.9% of stake
Feb 13No plan
Gaurav Shah
CEO · sold 12,279 at $3.31
41K
0.8% of stake
Jan 2
Elisabeth Bjork
Director · bought 10,000 at $3.44
34K
25% of stake
Nov 18, 2025No plan
John Militello
See Remarks · sold 1,086 at $2.98
3K
1.6% of stake
Nov 18, 2025No plan
Jonathan David Schwartz
See Remarks · sold 2,545 at $2.98
8K
0.8% of stake
Nov 18, 2025No plan
Gaurav Shah
CEO · sold 6,276 at $2.98
19K
0.5% of stake
Nov 18, 2025No plan
Martin Wilson
General Counsel · sold 1,646 at $2.98
5K
0.4% of stake
Oct 14, 2025No plan
John Militello
See Remarks · sold 28,918 at avg $3.96
115K
30% of stake
Aug 27, 2025
Elisabeth Bjork
Director · bought 10,000 at $3.41
34K
33% of stake
Aug 18, 2025 – Aug 19, 2025No plan
John Militello
See Remarks · sold 1,060 at avg $3.05
3K
1.9% of stake
Aug 18, 2025 – Aug 19, 2025No plan
Jonathan David Schwartz
See Remarks · sold 2,485 at avg $3.05
8K
1.1% of stake
Aug 18, 2025 – Aug 19, 2025No plan
Martin Wilson
General Counsel · sold 1,592 at avg $3.04
5K
1.2% of stake
Aug 14, 2025No plan
Jonathan David Schwartz
See Remarks · sold 11,161 at $3.02
34K
4.7% of stake
Aug 14, 2025No plan
John Militello
See Remarks · sold 7,043 at $3.02
21K
11% of stake
Aug 14, 2025No plan
Martin Wilson
General Counsel · sold 12,109 at $3.02
37K
8.1% of stake
Jul 3, 2025No plan
Aaron Ondrey
Chief Financial Officer · sold 1,477 at $2.88
4K
1.1% of stake
May 20, 2025No plan
John Militello
See Remarks · sold 357 at $6.45
2K
0.6% of stake
May 20, 2025No plan
Jonathan David Schwartz
See Remarks · sold 801 at $6.45
5K
0.3% of stake
May 20, 2025No plan
Kinnari Patel
See Remarks · sold 767 at $6.45
5K
0.1% of stake
May 20, 2025No plan
Gaurav Shah
CEO · sold 2,253 at $6.45
15K
0.2% of stake
May 20, 2025No plan
Martin Wilson
General Counsel · sold 587 at $6.45
4K
0.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RCKT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with RCKT

CompareIntrinsic value

BBIOBridgeBio Pharma, Inc.

$74.95+5.97%30

LGNDLigand Pharmaceuticals Inc.

$322.75+1.71%36

MRKMerck & Co., Inc.

$149.52+2.18%41

CRVOCervoMed Inc.

$1.60-8.57%10

IBOImpact Biomedical Inc.

$3.80-1.81%20

ATXIAvenue Therapeutics Inc.

$0.38+0.00%10

KPRXKiora Pharmaceuticals Inc.

$1.56-11.36%10

CPIXCumberland Pharmaceuticals Inc.

$4.69+7.82%13

Held by ETFs

RCKT is in 15 US ETFs. The largest of them, with RCKT's weight in each:

Spot a number that looks wrong? Check it in RCKT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RCKT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.